Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

187 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study.
Musso M, Scalone R, Marcacci G, Lanza F, Di Renzo N, Cascavilla N, Di Bartolomeo P, Crescimanno A, Perrone T, Pinto A. Musso M, et al. Among authors: perrone t. Bone Marrow Transplant. 2010 Jul;45(7):1147-53. doi: 10.1038/bmt.2009.318. Epub 2009 Nov 9. Bone Marrow Transplant. 2010. PMID: 19898504 Clinical Trial.
Single dose of palonosetron plus dexamethasone to control nausea, vomiting and to warrant an adequate food intake in patients treated with highly emetogenic chemotherapy (HEC). Preliminary results.
Lorusso V, Spedicato A, Petrucelli L, Saracino V, Giampaglia M, Perrone T. Lorusso V, et al. Among authors: perrone t. Support Care Cancer. 2009 Dec;17(12):1469-73. doi: 10.1007/s00520-009-0611-9. Epub 2009 Mar 18. Support Care Cancer. 2009. PMID: 19294429 Clinical Trial.
Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy: meta-analysis of individual patient data examining the effect of age on outcome in two phase III trials.
Celio L, Bonizzoni E, Bajetta E, Sebastiani S, Perrone T, Aapro MS. Celio L, et al. Among authors: perrone t. Support Care Cancer. 2013 Feb;21(2):565-73. doi: 10.1007/s00520-012-1558-9. Epub 2012 Aug 8. Support Care Cancer. 2013. PMID: 22869054 Free PMC article.
Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study.
Barni S, Labianca R, Agnelli G, Bonizzoni E, Verso M, Mandalà M, Brighenti M, Petrelli F, Bianchini C, Perrone T, Gasparini G. Barni S, et al. Among authors: perrone t. J Transl Med. 2011 Oct 20;9:179. doi: 10.1186/1479-5876-9-179. J Transl Med. 2011. PMID: 22013950 Free PMC article. Clinical Trial.
187 results